{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T10:11:41Z","timestamp":1787825501729,"version":"build-2784847793"},"reference-count":34,"publisher":"Georg Thieme Verlag KG","issue":"09","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Z Gastroenterol"],"published-print":{"date-parts":[[2025,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Hepatitis D virus (HDV) infection is the most severe form of viral hepatitis and has been shown to be associated with reduced quality of life. With the approval of the entry inhibitor bulevirtide, the first specific agent for HDV infection became available. Here, we report data on quality of life (QOL) before and during antiviral therapy with bulevirtide in a single center real-world cohort.<\/jats:p>\n                  <jats:p>We investigated QOL assessed by the Short Form 36 Health Survey (SF-36) in 25 patients undergoing antiviral treatment with bulevirtide. Surveys were completed before the beginning of antiviral therapy and up to week 152 of treatment as a long-term follow up.<\/jats:p>\n                  <jats:p>The study cohort included 7 women (28%) and 18 men (72%) with a median age of 46 years. Liver cirrhosis (defined as liver stiffness measurement \u2265 15.2 kPa) was present in 16 patients (64%) at the start of antiviral treatment. During the course of antiviral treatment with bulevirtide, scores for vitality, mental health and bodily pain significantly improved. The physical component score showed a minimal clinically important increase of \u2265 2.5 points in 10 patients (42%) at week 24 and in 6 patients (30% of patients with full data available) at week 48. The mental component score showed a minimal clinically important increase (\u2265 2.5 points compared to baseline) in 10 patients (42%) at week 24 and in 12 patients (60%) at week 48. In the patient cohort with an improvement of physical or mental component scores at week 48, a further improvement beyond week 48 was evident in single cases but not in all patients. Importantly, changes of physical or mental component scores were not associated with virological or biochemical responses.<\/jats:p>\n                  <jats:p>Vitality, mental health and bodily pain improved during BLV treatment. As a sign of the good tolerability of BLV, no significant deteriorations in QOL scores were observed. Findings need to be confirmed and further evaluated in larger cohorts and longer follow-up is needed.<\/jats:p>","DOI":"10.1055\/a-2633-6361","type":"journal-article","created":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T22:44:27Z","timestamp":1757630667000},"page":"930-941","source":"Crossref","is-referenced-by-count":2,"title":["Quality of life improves during antiviral therapy with bulevirtide"],"prefix":"10.1055","volume":"63","author":[{"given":"Julia Carolin","family":"Eichholz","sequence":"additional","affiliation":[{"name":"Hannover Medical School Department of Gastroenterology, Hepatology, Infectious Diseases and Endocrinology, Hanover, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Dietz-Fricke","sequence":"additional","affiliation":[{"name":"Hannover Medical School Department of Gastroenterology, Hepatology, Infectious Diseases and Endocrinology, Hanover, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon Kristian","family":"Mrowietz","sequence":"additional","affiliation":[{"name":"Hannover Medical School Department of Gastroenterology, Hepatology, Infectious Diseases and Endocrinology, Hanover, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katja","family":"Dinkelborg","sequence":"additional","affiliation":[{"name":"Hannover Medical School Department of Gastroenterology, Hepatology, Infectious Diseases and Endocrinology, Hanover, Germany"},{"name":"TWINCORE Center of Experimental and Clinical Infection Research, Hanover, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerstin","family":"Port","sequence":"additional","affiliation":[{"name":"Hannover Medical School Department of Gastroenterology, Hepatology, Infectious Diseases and Endocrinology, Hanover, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heiner","family":"Wedemeyer","sequence":"additional","affiliation":[{"name":"Hannover Medical School Department of Gastroenterology, Hepatology, Infectious Diseases and Endocrinology, Hanover, Germany"},{"name":"German Centre for Infection Research, Brunswick, Germany"},{"name":"Excellence Cluster Resist, Hannover Medical School, Hanover, Germany"},{"name":"D-SOLVE Consortium, Hanover, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katja","family":"Deterding","sequence":"additional","affiliation":[{"name":"Hannover Medical School Department of Gastroenterology, Hepatology, Infectious Diseases and Endocrinology, Hanover, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2025,9,11]]},"reference":[{"issue":"09","key":"ref1","doi-asserted-by":"publisher","first-page":"100818","DOI":"10.1016\/j.jhepr.2023.100818.","article-title":"Hepatitis D virus infection: Pathophysiology, epidemiology and treatment. report from the first international delta cure meeting 2022","volume":"5","author":"P Lampertico","year":"2023","journal-title":"JHEP Rep"},{"issue":"01","key":"ref2","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1111\/apt.15521.","article-title":"Long\u2010term clinical outcomes in patients with chronic hepatitis delta: The role of persistent viraemia","volume":"51","author":"A Palom","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1007\/s12072-023-10575-0.","article-title":"Clinical long-term outcome of hepatitis D compared to hepatitis B monoinfection","author":"A Wranke","year":"2023","journal-title":"Hepatol Int"},{"issue":"03","key":"ref4","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1016\/j.jhep.2020.04.008.","article-title":"The global prevalence of hepatitis D virus infection: Systematic review and meta-analysis","volume":"73","author":"AJ Stockdale","year":"2020","journal-title":"J Hepatol"},{"issue":"12","key":"ref5","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1136\/gut.18.12.997.","article-title":"Immunofluorescence detection of new antigen-antibody system (delta\/anti-delta) associated to hepatitis B virus in liver and in serum of HBsAg carriers","volume":"18","author":"M Rizzetto","year":"1977","journal-title":"Gut"},{"issue":"09","key":"ref6","doi-asserted-by":"publisher","first-page":"1782","DOI":"10.1136\/gutjnl-2020-323888.","article-title":"Hepatitis D virus in 2021: Virology, immunology and new treatment approaches for a difficult-to-treat disease","volume":"70","author":"S Urban","year":"2021","journal-title":"Gut"},{"issue":"01","key":"ref7","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.virol.2005.09.033.","article-title":"Hepatitis delta virus","volume":"344","author":"JM Taylor","year":"2006","journal-title":"Virology"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2020.104812.","article-title":"Current knowledge on hepatitis delta virus replication","volume":"179","author":"J Lucifora","year":"2020","journal-title":"Antiviral Res"},{"issue":"09","key":"ref9","first-page":"508","article-title":"Hepatitis delta: Current knowledge and future directions","volume":"18","author":"M Lange","year":"2022","journal-title":"Gastroenterol Hepatol (NY)"},{"issue":"S 01","key":"ref10","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1111\/liv.15410.","article-title":"Interferon\u2010based treatment of chronic hepatitis D","volume":"43","author":"L Sandmann","year":"2023","journal-title":"Liver Int"},{"issue":"06","key":"ref11","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1007\/s11096-005-1319-7.","article-title":"Side effects of interferon-\u03b1 therapy","volume":"27","author":"S Sleijfer","year":"2005","journal-title":"Pharm World Sci"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"155","DOI":"10.2147\/DDDT.S379964.","article-title":"Bulevirtide in the treatment of hepatitis delta: Drug discovery, clinical development and place in therapy","volume":"17","author":"V Soriano","year":"2023","journal-title":"Drug Des Devel Ther"},{"issue":"01","key":"ref13","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1053\/j.gastro.2014.04.030.","article-title":"Strategies to inhibit entry of HBV and HDV into hepatocytes","volume":"147","author":"S Urban","year":"2014","journal-title":"Gastroenterology"},{"issue":"02","key":"ref14","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/j.jhep.2023.05.001.","article-title":"EASL clinical practice guidelines on hepatitis delta virus","volume":"79","author":"European Association for the Study of the Liver","year":"2023","journal-title":"J Hepatol"},{"issue":"03","key":"ref15","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1016\/j.jhep.2016.04.016.","article-title":"Treatment of chronic hepatitis D with the entry inhibitor myrcludex B \u2013 first results of a phase ib\/IIa study","volume":"65","author":"P Bogomolov","year":"2016","journal-title":"J Hepatol"},{"issue":"01","key":"ref16","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/S1473-3099(22)00318-8.","article-title":"Safety and efficacy of bulevirtide in combination with tenofovir disoproxil fumarate in patients with hepatitis B virus and hepatitis D virus coinfection (MYR202): A multicentre, randomised, parallel-group, open-label, phase 2 trial","volume":"23","author":"H Wedemeyer","year":"2023","journal-title":"Lancet Infect Dis"},{"issue":"01","key":"ref17","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1056\/NEJMoa2213429.","article-title":"A phase 3, randomized trial of bulevirtide in chronic hepatitis D","volume":"389","author":"H Wedemeyer","year":"2023","journal-title":"N Engl J Med"},{"issue":"01","key":"ref18","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1111\/apt.16945.","article-title":"Response\u2010guided long\u2010term treatment of chronic hepatitis D patients with bulevirtide\u2014results of a \u201creal world\u201d study","volume":"56","author":"M Jachs","year":"2022","journal-title":"Aliment Pharmacol Ther"},{"issue":"04","key":"ref19","doi-asserted-by":"publisher","first-page":"100686","DOI":"10.1016\/j.jhepr.2023.100686.","article-title":"Treating hepatitis D with bulevirtide \u2013 real-world experience from 114 patients","volume":"5","author":"C Dietz-Fricke","year":"2023","journal-title":"JHEP Rep"},{"issue":"S 01","key":"ref20","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1111\/jvh.13811.","article-title":"Bulevirtide\u2010based treatment strategies for chronic hepatitis delta: A review","volume":"30","author":"E Degasperi","year":"2023","journal-title":"J Viral Hepat"},{"issue":"04","key":"ref21","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1016\/j.jhep.2024.05.001.","article-title":"Bulevirtide monotherapy in patients with chronic HDV: Efficacy and safety results through week 96 from a phase III randomized trial","volume":"81","author":"H Wedemeyer","year":"2024","journal-title":"J Hepatol"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"85","DOI":"10.2147\/PPA.S127139.","article-title":"Health-related quality of life in patients with chronic hepatitis B during antiviral treatment and off-treatment","volume":"11","author":"X Xue","year":"2017","journal-title":"Patient preference and adherence"},{"issue":"08","key":"ref23","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1111\/jvh.13546.","article-title":"Only partial improvement in health\u2010related quality of life after treatment of chronic hepatitis C virus infection with direct acting antivirals in a real\u2010world setting \u2013 results from the german hepatitis C\u2010Registry (DHC\u2010R)","volume":"28","author":"V Ohlendorf","year":"2021","journal-title":"J Viral Hepat"},{"issue":"08","key":"ref24","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1111\/liv.15602.","article-title":"Quality\u2010of\u2010life scores improve after 96 weeks of PEG\u2010IFNa\u20102a treatment of hepatitis D: An analysis of the HIDIT\u2010II trial","volume":"43","author":"K Dinkelborg","year":"2023","journal-title":"Liver Int"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"S72","DOI":"10.1016\/j.dld.2023.01.143.","article-title":"Bulevirtide improves health-related quality of life measured by EQ-5D VAS in patients with chronic hepatitis delta: An exploratory analysis of a phase 3 trial at 48 weeks","volume":"55","author":"M Buti","year":"2023","journal-title":"Dig Liver Dis"},{"issue":"01","key":"ref26","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.jhep.2024.06.031.","article-title":"Patient-reported outcomes in chronic hepatitis delta: An exploratory analysis of the phase III MYR301 trial of bulevirtide","volume":"82","author":"M Buti","year":"2025","journal-title":"J Hepatol"},{"issue":"6890","key":"ref27","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1136\/bmj.306.6890.1440.","article-title":"The SF36 health survey questionnaire: An outcome measure suitable for routine use within the NHS?","volume":"306","author":"AM Garratt","year":"1993","journal-title":"BMJ"},{"issue":"01","key":"ref28","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1097\/00005650-199401000-00004.","article-title":"The MOS 36-item short-form health survey (SF-36): III. tests of data quality, scaling assumptions, and reliability across diverse patient groups","volume":"32","author":"CA McHorney","year":"1994","journal-title":"Medical care"},{"key":"ref29","volume-title":"SF-36 health survey manual and interpretation guide","author":"JE Ware","year":"1993"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1111\/apt.17878.","article-title":"Liver stiffness measurement as a noninvasive method for the diagnosis of liver cirrhosis in patients with chronic hepatitis D virus infection","author":"L Sandmann","year":"2024","journal-title":"Aliment Pharmacol Ther"},{"issue":"08","key":"ref31","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.1111\/liv.15330.","article-title":"T\u2010cell driven allergic cutaneous reaction complicating treatment of hepatitis delta virus infection with bulevirtide","volume":"42","author":"P Behrendt","year":"2022","journal-title":"Liver Int"},{"issue":"01","key":"ref32","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1016\/j.jhep.2022.03.004.","article-title":"Immediate-type hypersensitivity reaction to bulevirtide and successful desensitization in a patient with HBV\/HDV-associated compensated cirrhosis","volume":"77","author":"C Schwarz","year":"2022","journal-title":"J Hepatol"},{"issue":"04","key":"ref33","first-page":"405","article-title":"Reduced quality of life in patients with chronic viral liver disease as assessed by SF12 questionnaire","volume":"17","author":"N Svirtlih","year":"2008","journal-title":"J Gastrointestin Liver Dis"},{"issue":"05","key":"ref34","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1016\/j.jhep.2014.06.034.","article-title":"Health related quality of life in people with advanced chronic liver disease","volume":"61","author":"JG Orr","year":"2014","journal-title":"J Hepatol"}],"container-title":["Zeitschrift f\u00fcr Gastroenterologie"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2633-6361.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T12:57:08Z","timestamp":1764075428000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2633-6361"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":34,"journal-issue":{"issue":"09","published-online":{"date-parts":[[2025,9,11]]},"published-print":{"date-parts":[[2025,9]]}},"URL":"https:\/\/doi.org\/10.1055\/a-2633-6361","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0044-2771","1439-7803"],"issn-type":[{"value":"0044-2771","type":"print"},{"value":"1439-7803","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9]]}}}